The Brain Tumour Charity has thanked the public for their input on the National Institute for Health and Care Excellence (NICE) draft decision on vorasidenib, a treatment for glioma brain tumours.
NICE is responsible for providing guidance on the use of new medicines in the NHS, and their draft decision on vorasidenib is currently subject to public consultation.
The charity has encouraged people to share their views on the treatment's effectiveness and value, as well as any personal experiences of glioma brain tumours.
Glioma brain tumours are a type of brain cancer that affects approximately 4,000 people in the UK each year. Vorasidenib is a targeted therapy that has shown promise in clinical trials, but its use in the NHS is still being considered.
The charity's call for public input comes as the UK Government continues to invest in cancer research and treatment. The Department of Health and Social Care has pledged to increase funding for cancer services and research, with a focus on improving outcomes for patients.
In response to the draft decision, the charity's Chief Executive, Sue Farrington, stated: 'We are grateful to those who have shared their thoughts on vorasidenib and its potential to benefit people with glioma brain tumours. We will continue to advocate for the interests of brain tumour patients and families, and we look forward to working with NICE and the Government to ensure that this treatment is available to those who need it.'